Global Neurology Academy

The Global Neurology Academy (GNA) Series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.

For more information about GNA, visit www.globalneurologyacademy.org.

367

LikeLikedUnlike

Episodes 1-15 of 24

- David Weisman, MD
  Peer
- Mijail D Serruya MD,PhD
  Peer
4
NeuroFrontiers
Refocusing Our Efforts on Advancing Technology to Help Stroke Survivors
Refocusing Our Efforts on Advancing Technology to Help Stroke Survivors
- David Weisman, MD
  Peer
- Mijail D Serruya MD,PhD
  Peer
3
NeuroFrontiers
The Future of Restoring Functionality in Stroke Survivors
The Future of Restoring Functionality in Stroke Survivors
- Timothy William West, MD
  Peer
10
On the Frontlines of Multiple Sclerosis
Staying Ahead of Progression in RMS
Staying Ahead of Progression in RMS
- Matt Birnholz, MD
  Peer
- Maria K. Houtchens, MD
  Peer
- Maria Lopes, MD
  Peer
3
Medical Industry Feature
Family Planning in Multiple Sclerosis: Enhancing Patient Care
Family Planning in Multiple Sclerosis: Enhancing Patient Care
- Giancarlo Comi, MD
  Peer
11
Global Neurology Academy
Treatment of Progressive MS: Why, Who, When, How
Treatment of Progressive MS: Why, Who, When, How
- Prof. Ralf Gold
  Peer
13
Global Neurology Academy
SPECIAL REPORT: Expert Opinion on New MS Drug Approval
SPECIAL REPORT: Expert Opinion on New MS Drug Approval
14
Global Neurology Academy
Now Approved in Europe: First Oral Short-Course Treatment for Highly Active Relapsing MS
Now Approved in Europe: First Oral Short-Course Treatment for Highly Active Relapsing MS
12
Global Neurology Academy
Cladribine Receives Positive CHMP Opinion for Relapsing MS Treatment
Cladribine Receives Positive CHMP Opinion for Relapsing MS Treatment
- Jiwon Oh, MD
  Peer
10
Global Neurology Academy
The Diagnostic Challenges of Spinal Cord Lesions in MS
The Diagnostic Challenges of Spinal Cord Lesions in MS
14
Global Neurology Academy
Reducing the Burden of MS Treatment
Reducing the Burden of MS Treatment
16
Global Neurology Academy
Benefit/Risk Strategies in Selecting Therapeutic Solutions for MS
Benefit/Risk Strategies in Selecting Therapeutic Solutions for MS
17
Global Neurology Academy
Therapeutic Mechanism of Action (MOAs) in MS: Targeting T- and B-cells to Reset the Immune System
Therapeutic Mechanism of Action (MOAs) in MS: Targeting T- and B-cells to Reset the Immune System
24
Global Neurology Academy
Multiple Sclerosis Physician Resources
Multiple Sclerosis Physician Resources
13
Global Neurology Academy
Establishing Partnerships to Optimize Patient Outcomes
Establishing Partnerships to Optimize Patient Outcomes
16
Global Neurology Academy
Optimizing MS Treatment Options
Optimizing MS Treatment Options